Evofem Biosciences (EVFM) Investor presentation summary

Strategic focus and product portfolio

• Commercializing two FDA-approved products: PHEXX, a hormone-free contraceptive vaginal gel, and SOLOSEC, a single-dose oral treatment for bacterial vaginosis and trichomoniasis.

• PHEXX is the first and only hormone-free, on-demand prescription contraceptive vaginal gel, with net sales growing year-over-year since its 2020 U.S. launch.

• SOLOSEC was acquired in July 2024, relaunched in November 2024, and targets common sexual health conditions with a single oral dose.

• Both products are expanding into international markets, with first launches expected in the UAE and broader MENA region.

• Strong intellectual property protection for both products, with patents extending into 2033 for PHEXX and 2040 for SOLOSEC.

Market opportunity and growth

• U.S. contraceptive market valued at $8.8B in 2024, with 26.2M potential PHEXX users identified.

• Every 1% market share in the U.S. addressable market represents $349M in annual net sales for PHEXX.

• Five consecutive years of net sales growth, despite no marketing spend since Q4 2022.

• GLP-1 user segment presents a $945M net sales opportunity for PHEXX, targeting women advised to use hormone-free contraception.

Commercial strategy and patient engagement

• Multichannel marketing leverages social media, conferences, and targeted collateral to reach diverse patient types.

• Social media campaigns, such as "Say Vagina," have significantly increased brand engagement and website traffic.

• Field and virtual sales coverage, along with strategic initiatives, support product adoption in key segments including student health and residency programs.

• Focused on reaching patients seeking non-hormonal, non-systemic contraception, including those with specific health needs.